Literature DB >> 16105482

Metabolic syndrome: demographic features, etiology, and clinical management.

Kathleen L Wyne1.   

Abstract

The metabolic syndrome, also known as the dysmetabolic syndrome, syndrome X, or the insulin resistance syndrome, refers to the clustering of cardiovascular disease risk factors that are present in many individuals who are at increased risk for cardiovascular events and/or type 2 diabetes. The criteria for metabolic syndrome include a combination of categorical and borderline risk factors that can be readily measured in clinical practice. Although the Adult Treatment Panel III of the National Cholesterol Education Program set the criteria to identify cardiovascular risk, the syndrome had already been well recognized in the endocrine community as identifying people at risk for diabetes. Recently, the International Diabetes Federation proposed a worldwide definition with ethnic-specific criteria for waist circumference. Therapies targeted to specific components of the metabolic syndrome, such as improving glycemic control, managing dyslipidemia, and reducing the prothrombotic state, should help to minimize cardiovascular risk, particularly if initiated early.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16105482     DOI: 10.1007/s11883-005-0051-z

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  41 in total

1.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

2.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

3.  The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study.

Authors:  David W Dunstan; Paul Z Zimmet; Timothy A Welborn; Maximilian P De Courten; Adrian J Cameron; Richard A Sicree; Terry Dwyer; Stephen Colagiuri; Damien Jolley; Matthew Knuiman; Robert Atkins; Jonathan E Shaw
Journal:  Diabetes Care       Date:  2002-05       Impact factor: 19.112

4.  Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.

Authors:  C M Ballantyne; J A Herd; L L Ferlic; J K Dunn; J A Farmer; P H Jones; J R Schein; A M Gotto
Journal:  Circulation       Date:  1999-02-16       Impact factor: 29.690

5.  Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.

Authors:  John K Ninomiya; Gilbert L'Italien; Michael H Criqui; Joanna L Whyte; Anthony Gamst; Roland S Chen
Journal:  Circulation       Date:  2003-12-15       Impact factor: 29.690

6.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

7.  Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study.

Authors:  David E Laaksonen; Hanna-Maaria Lakka; Leo K Niskanen; George A Kaplan; Jukka T Salonen; Timo A Lakka
Journal:  Am J Epidemiol       Date:  2002-12-01       Impact factor: 4.897

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

10.  The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort.

Authors:  Paul Holvoet; Stephen B Kritchevsky; Russell P Tracy; Ann Mertens; Susan M Rubin; Javed Butler; Bret Goodpaster; Tamara B Harris
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.